Characteristics, Treatment Patterns, and Economic Outcomes of Patients Initiating Injectable Medications for Management of Type 2 Diabetes Mellitus in Japan: Results from a Retrospective Claims Database Analysis.

Suzuki, Shuichi; Desai, Urvi; Strizek, Alena; Ivanova, Jasmina; Garcia-Horton, Viviana; Cai, Zhihong; Schmerold, Luke; Liu, Xinyue; Perez-Nieves, Magaly

Suzuki, Shuichi; Desai, Urvi; Strizek, Alena; Ivanova, Jasmina; Garcia-Horton, Viviana; Cai, Zhihong; Schmerold, Luke; Liu, Xinyue; Perez-Nieves, Magaly.

Afiliación

Suzuki S; Eli Lilly Japan, K.K., Kobe, Japan. Suzuki_shuichi@lilly.com.
Desai U; Analysis Group, Inc., Boston, MA, USA.
Strizek A; Eli Lilly and Company, Indianapolis, IN, USA.
Ivanova J; Analysis Group, Inc., New York, NY, USA.
Garcia-Horton V; Analysis Group, Inc., New York, NY, USA.
Cai Z; Eli Lilly Japan, K.K., Kobe, Japan.
Schmerold L; Analysis Group, Inc., New York, NY, USA.
Liu X; Analysis Group, Inc., New York, NY, USA.
Perez-Nieves M; Eli Lilly and Company, Indianapolis, IN, USA.

Diabetes Ther ; 9(3): 1125-1141, 2018 Jun.

Article en En | MEDLINE | ID: mdl-29663262

Palabras clave

Costs; Injectable antidiabetic; Resource use; Specialist vs. GP setting; Treatment patterns; Type 2 diabetes

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Risk_factors_studies Idioma: En Revista: Diabetes Ther Año: 2018 Tipo del documento: Article País de afiliación: Japón

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google